Genomic & Biopharma NewsSomaGenics Granted New Patents for RNA Detection and RNA-based Therapeutics Technologies
SomaGenics, an RNA-focused biotechnology company, announced expansion of its intellectual property portfolio with issue of two new patents for its RNA analysis technologies (miR-ID® and RealSeq®) and European patent protection for its therapeutic short synthetic hairpin RNA (sshRNA) agents. MiR-ID®, SomaGenics’ core technology for quantitative real-time PCR, enables accurate analysis of microRNAs (miRNAs) and single-nucleotide ...
|Transcriptome Research & Industry News, 2016-12-01 10:00:02|
AstraZeneca inks big, backloaded deal for bicyclic peptides
AstraZeneca inks big, backloaded deal for bicyclic peptides nick.paul.taylor Thu, 12/01/2016 - 04:53
|Fierce Biotech, 2016-12-01 09:53:04|
Alcohol consumption linked to higher risk of melanoma
Alcohol intake was associated with higher rates of invasive melanoma among white men and women.
|News Medical Life Sciences, 2016-12-01 09:22:21|
Cancer research gets £226 million investment
Cancer Research UK has committed funding of £190 million over the next five years for its network of 13 UK Centres, which aim to accelerate the pathway for getting cutting edge discoveries from the laboratory to patients.
|PharmaTimes, 2016-12-01 09:18:21|
After Juno deaths, Bluebird posts positive CAR-T safety, efficacy signals
After Juno deaths, Bluebird posts positive CAR-T safety, efficacy signals badams Thu, 12/01/2016 - 02:12
|Fierce Biotech, 2016-12-01 07:12:20|
Conditional EU nod for Takeda’s Ninlaro
Takeda Pharmaceutical's Ninlaro has been awarded conditional marketing approval in Europe as a second-line treatment for multiple myeloma.
|PharmaTimes, 2016-12-01 07:04:42|
NICE backs GSK’s novel asthma biologic
It is looking likely that some patients with a difficult-to-treat form of asthma will get routine access to a novel treatment option on the NHS, after GlaxoSmithKline Nucala's was backed by cost regulators.
|PharmaTimes, 2016-12-01 07:01:08|
AbbVie’s risankizumab bags Orphan status for paediatric Crohn’s
An experimental therapy being developed by AbbVie for paediatric patients with Crohn's disease has been awarded Orphan Drug status in the US.
|PharmaTimes, 2016-12-01 06:50:38|
Hunt announces £1m pilot scheme to retain GPs over 55
Health secretary Jeremy Hunt has announced a £1 million pilot scheme to encourage GPs nearing retirement to stay in practice by increasing work flexibility and variety.
|PharmaTimes, 2016-12-01 06:45:31|